NRx Pharmaceuticals Ends 2025 Debt-Free with $7.8M Cash, Eyes Q3 2026 Ketamine Approval
NRx Pharmaceuticals ended 2025 debt-free after converting all convertible debt into common stock and held $7.8 million cash, reducing its operating loss by $2.3 million to $16.2 million. The company expects FDA ANDA approval of preservative-free ketamine in Q3 2026 following favorable preliminary bioequivalence feedback.
1. Full-Year Financial Results
NRx Pharmaceuticals reduced its operating loss from $18.5 million in 2024 to $16.2 million in 2025, driven by a $2.4 million decrease in research and development expense to $3.8 million and a $0.4 million reduction in general and administrative costs to $13.1 million.
2. Debt Conversion and Cash Runway
As of December 31, 2025, all previously issued convertible debt had been converted into common stock, leaving the company debt-free with $7.8 million in cash and cash equivalents. Management believes ongoing operational revenues and current at-the-market financings will fund operations through 2026.
3. FDA Regulatory Milestones
The company received a favorable preliminary bioequivalence determination for its preservative-free ketamine ANDA and held a Type C meeting with FDA psychiatry officials, who signaled willingness to rely on existing clinical and real-world data for NRX-100 approval, targeting Q3 2026.
4. Pipeline Advancements and Commercial Expansion
NRx appointed Prof. Joshua Brown as Chief Medical Innovation Officer, filed an IND for NRX-101 to enhance TMS therapy, and is developing a sustained-release D-cycloserine formulation. The company opened five HOPE Therapeutics clinics and partnered with neurocare AG to integrate 20 sites and over 400 TMS machines into a nationwide neuroplastic therapy network.